Oral administration of a novel RORγt antagonist attenuates psoriasis-like skin lesion of two independent mouse models through neutralization of IL-17

Journal of Dermatological Science

Volumn 85, Issue 1, 2017, Pages 12-19

  Takaishi, Mikiro ^a   Ishizaki, Masayuki ^b   Suzuki, Keisuke ^b   Isobe, Takashi ^b   Shimozato, Takaichi ^b   Sano, Shigetoshi ^a  

^a KOCHI UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Antagonist; Mouse model; Psoriasis; ROR t; Th17

Indexed keywords

2,4,6 TRICHLORO N [5 [[4 (CYCLOHEXANECARBONYL) 3 METHYL PIPERAZIN 1 YL]METHYL] 3 PYRIDYL]BENZENESULFONAMIDE SODIUM SALT; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; PROTEIN INHIBITOR; RETINOID RELATED ORPHAN RECEPTOR GAMMA; UNCLASSIFIED DRUG; 4-O-METHYL-12-O-TETRADECANOYLPHORBOL 13-ACETATE; IL17A PROTEIN, MOUSE; INTERLEUKIN 23; PHORBOL 13 ACETATE 12 MYRISTATE; STAT3 PROTEIN; STAT3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL DIFFERENTIATION; CELL DIFFERENTIATION ASSAY; CELL VIABILITY; COMPETITIVE BINDING ASSAY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LUCIFERASE ASSAY; LYMPHOID CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PSORIASIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH17 CELL; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; SKIN; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; PSORIASIS; RECEPTORS, INTERLEUKIN-17; SIGNAL TRANSDUCTION; SKIN; STAT3 TRANSCRIPTION FACTOR; TETRADECANOYLPHORBOL ACETATE; TH17 CELLS;

EID: 84992337491     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2016.10.001     Document Type: Article

References (25)

1. [1] Lowes, M.A., Suárez-Fariñas, M., Krueger, J.G., Immunology of psoriasis. Annu. Rev. Immunol. 32 (2014), 227–255.
2. [2] Lee, E., Trepicchio, W.L., Oestreicher, J.L., Pittman, D., Wang, F., Chamian, F., et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199 (2004), 125–130.
3. [3] Nakajima, K., Kanda, T., Takaishi, M., Shiga, T., Miyoshi, K., Nakajima, H., et al. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J. Immunol. 186 (2011), 4481–4489.
4. [4] van der Fits, L., Mourits, S., Voerman, J.S., Kant, M., Boon, L., Laman, J.D., et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 182 (2009), 5836–5845.
5. [5] Zheng, Y., Danilenko, D.M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., et al. Interleukin-22 a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445 (2007), 648–651.
6. [6] Mitra, A., Fallen, R.S., Lima, H.C., Cytokine-based therapy in psoriasis. Clin. Rev. Allergy Immunol. 44 (2013), 173–182.
7. [7] Girolomoni, G., Mrowietz, U., Paul, C., Psoriasis: rationale for targeting interleukin-17. Br. J. Dermatol. 167 (2012), 717–724.
8. [8] Yang, J., Sundrud, M.S., Skepner, J., Yamagata, T., Targeting Th17 cells in autoimmune diseases. Trends Pharmacol. Sci. 35 (2014), 493–500.
9. [9] Pantelyushin, S., Haak, S., Ingold, B., Kulig, P., Heppner, F.L., Navarini, A.A., et al. Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice. J. Clin. Invest. 122 (2012), 2252–2256.
10. [10] Ivanov, I.I., McKenzie, B.S., Zhou, L., Tadokoro, C.E., Lepelley, A., Lafaille, J.J., et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126 (2006), 1121–1133.
11. [11] Yang, X.O., Pappu, B.P., Nurieva, R., Akimzhanov, A., Kang, H.S., Chung, Y., et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity 28 (2008), 29–39.
12. [12] Huh, J.R., Leung, M.W.L., Huang, P., a Ryan, D., Krout, M.R., Malapaka, R.R.V., et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity. Nature 472 (2011), 486–490.
13. [13] Fujita-Sato, S., Ito, S., Isobe, T., Ohyama, T., Wakabayashi, K., Morishita, K., et al. Structural basis of digoxin that antagonizes RORgamma t receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production. J. Biol. Chem. 286 (2011), 31409–31417.
14. [14] a Solt, L., Kumar, N., Nuhant, P., Wang, Y., Lauer, J.L., Liu, J., et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 472 (2011), 491–494.
15. [15] Xu, T., Wang, X., Zhong, B., Nurieva, R.I., Ding, S., Dong, C., Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of RORγt protein. J. Biol. Chem. 286 (2011), 22707–22710.
16. [16] Skepner, J., Ramesh, R., Trocha, M., Schmidt, D., Baloglu, E., Lobera, M., et al. Pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo. J. Immunol. 192 (2014), 2564–2575.
17. [17] Xiao, S., Yosef, N., Yang, J., Wang, Y., Zhou, L., Zhu, C., et al. Small-molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. Immunity 40 (2014), 477–489.
18. [18] Sano, S., Chan, K.S., Carbajal, S., Clifford, J., Peavey, M., Kiguchi, K., et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 11 (2005), 43–49.
19. [19] Sun, Z., Unutmaz, D., Zou, Y.R., Sunshine, M.J., Pierani, A., Brenner-Morton, S., et al. Requirement for RORgamma in thymocyte survival and lymphoid organ development. Science 288 (2000), 2369–2373.
20. [20] Kurebayashi, S., Ueda, E., Sakaue, M., Patel, D.D., Medvedev, A., Zhang, F., et al. Retinoid-related orphan receptor gamma (RORgamma) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 10132–10137.
21. [21] Cai, Y., Shen, X., Ding, C., Qi, C., Li, K., Li, X., et al. Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity 35 (2011), 596–610.
22. [22] Basu, R., Hatton, R.D., Weaver, C.T., The Th17 family: flexibility follows function. Immunol. Rev. 252 (2013), 89–103.
23. [23] Withers, D.R., Hepworth, M.R., Wang, X., Mackley, E.C., Halford, E.E., Dutton, E.E., et al. Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells. Nat. Med. 22 (2016), 319–323.
24. [24] Villanova, F., Flutter, B., Tosi, I., Grys, K., Sreeneebus, H., Perera, G.K., et al. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J. Invest. Dermatol. 134 (2014), 984–991.
25. [25] Takaishi, M., Nakajima, K., Ouyang, W., Sano, S., Psoriasis-like skin lesions are dependent on IL-23 but develop in the absence of IL-22 in a model mouse. J. Dermatol. Sci. 73 (2014), 261–264.